KNBIF (KNBIF) Stock Price & Analysis
KNBIF (KNBIF) rose 24.38% to USD 0.03 as of June 10, 2026 at 06:50 UTC, according to Nexqual real-time market data.
KNBIF last closed at USD 0.02; the session ranged USD 0.03–0.03 on volume of 20,000 shares. Market capitalization is $5.13M, with a 52-week range of USD 0.02–0.05 (PNK). Source: Nexqual, June 10, 2026 at 06:50 UTC.
Key Statistics (as of June 10, 2026 at 06:50 UTC)
| Price | USD 0.03 |
|---|---|
| Change | ▲ 24.38% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.03 |
| Day Range | USD 0.03 – 0.03 |
| 52-Week Range | USD 0.02 – 0.05 |
| Volume | 20,000 shares |
| Market Cap | $5.13M |
| Exchange | PNK |
Technical Analysis (KNBIF)
Nexqual's technical model rates KNBIF "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 06:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.32 (neutral) |
| vs SMA50 | Above (USD 0.02) |
| MACD | -0 (negative) |
Analyst Ratings (KNBIF)
Wall Street analysts rate KNBIF "None", per Nexqual as of June 10, 2026 at 06:50 UTC.
| Consensus Rating | None |
|---|
Earnings (KNBIF)
| Next Earnings Date | 2026-05-28 |
|---|
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Financials & Fundamentals (KNBIF)
| Total Revenue | $58,574 |
|---|---|
| Revenue Growth (YoY) | -89.50% |
| Gross Margin | -80.22% |
| Operating Margin | -1557.92% |
| Profit Margin | +0.00% |
| Current Ratio | 0.45 |
| Total Cash | $395,058 |
| Total Debt | $1.92M |
| Free Cash Flow | $-2.13M |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Financial Health Score (KNBIF)
Nexqual rates KNBIF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:50 UTC.
| Growth | Critical — Revenue -90% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $395K cash vs $2M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (KNBIF)
| Insider Ownership | +44.93% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 205.06M |
| Float | 105.14M |
Source: Nexqual, June 10, 2026 at 06:50 UTC.
Leadership (KNBIF)
KNBIF is led by Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC (age 60), Interim CEO, Director & Member of Scientific Advisory Board, per Nexqual as of June 10, 2026 at 06:50 UTC.
| Interim CEO, Director & Member of Scientific Advisory Board | Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC (age 60) |
|---|---|
| Chief Financial Officer | Ray Dupuis |
| Chief Scientific Officer & Member of Scientific Advisory Board | Gregory S. Schultz (age 75) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRBCF | Sirona Biochem Corp. | USD 0.01 | ▲ 0% |
| ACHFF | Arch Biopartners Inc. | USD 0.34 | ▼ 3.41% |
| ACWRF | ACCELEWARE LTD | USD 0.06 | ▲ 5.36% |
| BTVRF | BLUERUSH INC. | USD 0 | ▲ 0% |
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:50 UTC. This page is informational and not investment advice.